Orchard Therapeutics PLC (ORTX)
| Market Cap | 610.93M |
| Revenue (ttm) | 3.19M |
| Net Income (ttm) | n/a |
| Shares Out | 99.66M |
| EPS (ttm) | -1.65 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 21 |
| Last Price | $6.25 |
| Previous Close | $6.50 |
| Change ($) | -0.25 |
| Change (%) | -3.85% |
| Day's Open | 6.60 |
| Day's Range | 6.17 - 6.62 |
| Day's Volume | 1,537,045 |
| 52-Week Range | 3.86 - 13.48 |
BOSTON and LONDON, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced plans to extend the company's commercial reach in the Mi...
The FDA bestows a Regenerative Medicine Advanced Therapy status on Orchard Therapeutics' (ORTX) investigational gene therapy, OTL-200, for treating early-onset metachromatic leukodystrophy. Sh...
Orchard Therapeutics (ORTX) stock is on the rise Wednesday with heavy trading even with there being no major news about the company. The post ORTX Stock Alert: 8 Things to Know About Gene Ther...
BOSTON and LONDON, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company is scheduled to present at the 39th Ann...
First gene therapy to receive full EU marketing authorization for eligible MLD patients
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.
Preliminary results from first patient treated with OTL-201 show over expression of the therapeutic enzyme and decrease in substrate levels three months following gene therapy Preliminary resu...
BOSTON and LONDON, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that its chief executive officer, Bobby Gaspar, M.D., Ph...
BOSTON and LONDON, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the U.S. Food and Drug Administration (FDA) has cle...
These companies are devoted to helping patients who don't have any other options.
BOSTON and LONDON, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company is scheduled to present at the Barclays...
Preliminary results from first patient in ongoing proof-of-concept trial show evidence of engraftment of gene-modified cells three months following treatment Preliminary results from first pat...
Orchard just received a positive node from CHMP for its lead drug candidate. US approval should be next.
BOSTON and LONDON, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company will webcast a virtual R&D event ‘New H...
BOSTON and LONDON, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company's chief executive officer, Bobby Gaspar...
First therapy recommended for full marketing authorization in the EU for eligible patients with confirmed diagnosis of late infantile or early juvenile MLD variants
BOSTON and LONDON, Sept. 28, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the European Medicines Agency (EMA) has granted ...
BOSTON and LONDON, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company is scheduled to present at the follo...
Data on all eight patients demonstrate sustained engraftment and supranormal IDUA enzyme expression
BOSTON and LONDON, Aug. 24, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced presentations at the upcoming 46th Annual Meeting of t...
Orchard Therapeutics plc (ORTX) CEO Bobby Gaspar on Q2 2020 Results - Earnings Call Transcript
BOSTON and LONDON, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company is scheduled to present at the Wedbus...
Orchard Therapeutics: An Undervalued Gene Therapy Company
BOSTON and LONDON, July 20, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company has received both orphan drug designa...
BOSTON and LONDON, July 15, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company has entered into two worldwide royalt...
BOSTON and LONDON and MILAN, Italy, July 09, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, and MolMed S.p.A (MLMD.MI), one of the company’s prin...
BOSTON and LONDON, May 27, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that presentations by the management team will be made ...
First Primary Outcome Measure Met with All Eight Patients Achieving Hematologic Engraftment
Orchard Therapeutics: A Leading Gene Therapy Company For Your Watchlist
Orchard Therapeutics' (ORTX) CEO Bobby Gaspar on Q1 2020 Results - Earnings Call Transcript
Shares of Orchard Therapeutics (NASDAQ:ORTX) fell 1.5% after the company reported Q1 results.
Orchard Therapeutics: Updating The Investment Thesis
BOSTON and LONDON, April 27, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the first patient has been dosed in an open-la...
The COVID-19 pandemic has changed normal operations for companies across the world as they cope with resource limitations, health precautions and other challenges.
BOSTON and LONDON, March 31, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global leader in gene therapy, today provided an update on its business and operations, outlining...
-- Mark Rothera steps down as President and CEO -- -- Frank Thomas takes on additional responsibilities as President and Chief Operating Officer --
Orchard Therapeutics PLC (ORTX) CEO Mark Rothera on Q4 2019 Results - Earnings Call Transcript
BOSTON and LONDON, Feb. 03, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced the appointment of Steven Altschuler, M.D., to its boa...
Early Clinical Data Support ex vivo Hematopoietic Stem Cell Gene Therapy as a Potentially Promising Treatment Option for X-CGD Early Clinical Data Support ex vivo Hematopoietic Stem Cell Gene ...
Application Being Evaluated Under Accelerated Assessment Application Being Evaluated Under Accelerated Assessment
BOSTON and LONDON, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients...
Orchard Therapeutics' (ORTX) CEO on Q3 2019 Results - Earnings Call Transcript
Registrational Trial for Wiskott-Aldrich Syndrome Met Key Primary and Secondary Endpoints at Three Years; Data from Integrated Analysis Reinforce Treatment Benefits of Gene Therapy and Durabil...
Stable Levels of Engraftment and Reconstitution of Enzyme Activity in Patients with Up to 12 Months of Follow-up Indicate Similar Profiles Between Cryopreserved and Fresh Formulations
BOSTON and LONDON, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients...
Initial Results from Cryopreserved Formulation Clinical Trial Accepted as Poster Presentation Initial Results from Cryopreserved Formulation Clinical Trial Accepted as Poster Presentation
BOSTON and LONDON, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patient...
BOSTON and LONDON, Sept. 13, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patient...
Six of Eight Patients Treated to Date with Follow-up Out to 12 Months in First Patient to Receive Treatment
About ORTX
Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified drug product to treat the patient's disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinical develop... [Read more...]
| Industry Biotechnology | IPO Date Oct 31, 2018 |
| CEO Prof. Bobby Gaspar Ph.D., M.D. | Employees 252 |
| Stock Exchange NASDAQ | Ticker Symbol ORTX |
Financial Performance
In 2019, ORTX's revenue was $2.51 million, an increase of 21.05% compared to the previous year's $2.08 million. Losses were -$163.42 million, -29.10% less than in 2018.
Analyst Forecasts
According to 9 analysts, the average rating for ORTX stock is "Strong Buy." The 12-month stock price forecast is 14.56, which is an increase of 132.96% from the latest price.